In this interview, Kerry Reynolds, MD chats with Meghan Sise, MD, director of onconephrology at Mass General Hospital, to learn more about how immune checkpoint inhibitor (ICI) therapy affects kidney function.
Explore This Treatment Program
The team in the Onconephrology Clinic at Massachusetts General Hospital provides high-quality patient-centered care to individuals with cancer and kidney disease in collaboration with all other providers involved in their care, such as oncologists within the Mass General Cancer Center.
This multidisciplinary, sub-specialized approach to care ensures better health outcomes for patients, as all will benefit from a coordinated treatment plan developed by clinicians with highly specialized expertise in all aspects of kidney disease and cancer. Patients who have received cancer care outside of the Mass General Cancer Center can continue to work with their established care team while also receiving specialized, expert care at the clinic.
Some patients with cancer may have underlying or previously diagnosed kidney disease while others may experience kidney disease as a result of their cancer or as a side effect of their cancer treatment. The Onconephrology Clinic team assists oncologists in the management of kidney-related side effects of cancer chemotherapy and immunotherapy, such as elevated blood creatinine or protein in the urine, and promptly evaluates patients who are either at risk of kidney injury or have suffered kidney injury during their treatment course.
The Onconephrology Clinic team provides virtual and in-person consultations for patients with cancer and kidney disease. Conditions that we manage include (but are not limited to):
- Chemotherapy, targeted therapy and immunotherapy related kidney toxicities
- Chronic kidney disease in patients with cancer, including those with renal cell cancer and prior nephrectomy
- Fluid and electrolyte abnormalities or imbalances in patients with cancer
- Kidney disease caused by multiple myeloma, amyloidosis or monoclonal gammopathy of uncertain significance (MGUS)
- Kidney disease in patients who have undergone stem cell transplant or CAR-T therapy
The Onconephrology Clinic team uses clinical and translational research approaches to study mechanisms of kidney toxicity and determine the best practices for caring for patients with cancer.
Ongoing research projects in the clinic include the study of:
- Risk factors for kidney injury in patients receiving targeted therapies and immunotherapies
- Causes of kidney injury triggered by cancer therapies
- Best practices for diagnosis and management of kidney injury in patients receiving chemotherapy and cancer immunotherapy
- Potential side effects of cancer therapy in patients with advanced kidney disease or on dialysis
- Long-term kidney effects of various cancer therapies in cancer survivors
Research labs led by onconephrology clinicians include: